Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cells

Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator

Leukemia volume 23, pages 305–312 (2009)Cite this article

Abstract

Fludarabine exposure leads to impaired peripheral blood stem cell (PBSC) mobilization in indolent lymphoproliferative disorders (LPD). We previously reported that only 34% of fludarabine-exposed patients mobilized successfully using granulocyte-colony stimulating factor (G-CSF; median 10 μg/kg/day) with or without chemotherapy, with unpredictable kinetics and moderate infectious morbidity. Stem cell factor (SCF) plus high-dose twice daily (b.d.) G-CSF may improve mobilization in these patients. SCF 20 μg/kg/day subcutaneously was given from day 1, G-CSF 12 μg/kg b.d. subcutaneously from day 4, apheresis commenced from day 6. Previous study patients served as historical controls. Thirty five patients with indolent LPD were enrolled, median age was 54 years (range 31–66), 66% male, median cumulative prior fludarabine dose was 660 (405–900) mg. Overall, 22 patients (63%) collected ⩾2.0 × 106/kg PBSC (success), compared to 34% controls (odds ratio (OR) 3.2; 95% confidence interval (CI) (1.2, 9.3); P=0.021). Median CD34+ yield overall was 2.3 × 106/kg (0.53–8.97) from median four (2–6) aphereses. Study patients ⩾50 years mobilized successfully more frequently than controls (58 versus 17%; P=0.0065). Adjusting for age, successful mobilization remained significantly higher in the current study (OR 4.2; 95% CI (1.4, 14.0); P=0.008). SCF/high-dose b.d. G-CSF improves PBSC mobilization efficacy after fludarabine exposure, over mobilization using G-CSF as the mobilizing cytokine. This combined growth factor strategy is a preferred mobilization method for fludarabine-exposed patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC . Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant 1998; 21: 1201–1205.

    Article  CAS  PubMed  Google Scholar 

  2. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  PubMed  Google Scholar 

  3. van Besien K, Keralavarma B, Devine S, Stock W . Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 2001; 15: 1317–1325.

    Article  CAS  PubMed  Google Scholar 

  4. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.

    Article  CAS  PubMed  Google Scholar 

  5. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432–1438.

    Article  CAS  PubMed  Google Scholar 

  6. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078.

    Article  CAS  PubMed  Google Scholar 

  7. Morgan S, Seymour JF, Grigg A, Matthews JP, Prince HM, Wolf MM, Januszewicz EH . Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia 2004; 18: 1034.

    Article  CAS  PubMed  Google Scholar 

  8. Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M . Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol 2007; 25: 1722–1731.

    Article  CAS  PubMed  Google Scholar 

  9. Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R et al. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002; 3: 26–35.

    Article  CAS  PubMed  Google Scholar 

  10. Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M et al. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006; 91: 1662–1673.

    PubMed  Google Scholar 

  11. Kay NE, Rai KR, O'Brien S . Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol 2006; 4 (11 Suppl 22): 1–12.

    PubMed  Google Scholar 

  12. Lenz G, Hiddemann W, Dreyling M . The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004; 101: 883–893.

    Article  CAS  PubMed  Google Scholar 

  13. Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006; 106: 2412–2420.

    Article  CAS  PubMed  Google Scholar 

  14. Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V et al. Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group. Leuk Lymphoma 2004; 45: 1141–1147.

    Article  CAS  PubMed  Google Scholar 

  15. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694–704.

    Article  CAS  PubMed  Google Scholar 

  16. Morstyn G, Brown S, Gordon M, Crawford J, Demetri G, Rich W et al. Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology 1994; 51: 205–214.

    Article  CAS  PubMed  Google Scholar 

  17. Duarte RF, Franf DA . The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance. Leuk Lymphoma 2002; 43: 1179–1187.

    Article  CAS  PubMed  Google Scholar 

  18. Briddell RA, Hartley CA, Smith KA, McNiece IK . Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood 1993; 82: 1720–1723.

    CAS  PubMed  Google Scholar 

  19. de Revel T, Appelbaum FR, Storb R, Schuening F, Nash R, Deeg J et al. Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994; 83: 3795–3799.

    CAS  PubMed  Google Scholar 

  20. Andrews RG, Briddell RA, Knitter GH, Rowley SD, Appelbaum FR, McNiece IK . Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 1995; 85: 15–20.

    CAS  PubMed  Google Scholar 

  21. Molineux G, Migdalska A, Szmitkowski M, Zsebo K, Dexter TM . The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor. Blood 1991; 78: 961–966.

    CAS  PubMed  Google Scholar 

  22. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939–2951.

    CAS  PubMed  Google Scholar 

  23. Weaver A, Chang J, Wrigley E, de Wynter E, Woll PJ, Lind M et al. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 1998; 16: 2601–2612.

    Article  CAS  PubMed  Google Scholar 

  24. Facon T, Harousseau J-L, Maloisel F, Attal M, Odriozola J, Alegre A et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999; 94: 1218–1225.

    CAS  PubMed  Google Scholar 

  25. Horsfall MJ, Hui CH, To LB, Begley CG, Basser RL, Simmons PJ . Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assay. Br J Haematol 2000; 109: 751–758.

    Article  CAS  PubMed  Google Scholar 

  26. Crawford J, Lau R, Erwin R, Rich W, McGuire B, Meyers F . A Phase I trial of recombinant methionyl human stem cell factor (SCF) in patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 1993; 12: 135 (abstr).

    Google Scholar 

  27. Colony Assays of Hematopoietic Cells using Methylcellulose Media—an Introductory Technical Manual. The Terry Fox Laboratory Media Preparation Service: Vancouver B.C, Canada, 1992 ed.

  28. Drake M, Ranaghan L, Morris TC, Nolan L, Desai ZR, Irvine AE et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745–749.

    Article  CAS  PubMed  Google Scholar 

  29. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242.

    Article  CAS  PubMed  Google Scholar 

  30. Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 2000; 37: 157–161.

    Article  CAS  PubMed  Google Scholar 

  31. Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ . Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002; 30: 440–449.

    Article  CAS  PubMed  Google Scholar 

  32. Papayannopoulou T . Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004; 103: 1580–1585.

    Article  CAS  PubMed  Google Scholar 

  33. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ . Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289–1297.

    Article  CAS  PubMed  Google Scholar 

  34. To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003; 31: 371–378.

    Article  CAS  PubMed  Google Scholar 

  35. Vantelon JM, Koscielny S, Brault P, Bourhis JH, Ribrag V, Pico J et al. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice. Bone Marrow Transplant 2000; 25: 495–499.

    Article  CAS  PubMed  Google Scholar 

  36. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363–365.

    Article  PubMed  Google Scholar 

  37. Michallet M, Thiebaut A, Dreger P, Remes K, Milpied N, Santini G et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: 595–601.

    Article  CAS  PubMed  Google Scholar 

  38. Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A . Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 2005; 36: 389–396.

    Article  CAS  PubMed  Google Scholar 

  39. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.

    CAS  PubMed  Google Scholar 

  40. Chapple P, Prince HM, Quinn M, Bertoncello I, Juneja S, Wolf M et al. Peripheral blood CD34+ cell count reliably predicts autograft yield. Bone Marrow Transplant 1998; 22: 125–130.

    Article  CAS  PubMed  Google Scholar 

  41. Boeve S, Strupeck J, Creech S, Stiff PJ . Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997–1003.

    Article  CAS  PubMed  Google Scholar 

  42. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J . Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260–1261.

    Article  PubMed  Google Scholar 

  43. Dincer AP, Gottschall J, Margolis DA . Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004; 26: 761–763.

    Article  PubMed  Google Scholar 

  44. Falzetti F, Aversa F, Minelli O, Tabilio A . Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.

    CAS  PubMed  Google Scholar 

  45. Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005; 23: 8533–8534.

    Article  PubMed  Google Scholar 

  46. Hatzimichael E, Benetatos L, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL . Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Clin Lab Haematol 2006; 28: 416–418.

    Article  CAS  PubMed  Google Scholar 

  47. Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 69–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    K E Herbert, S Morgan, H M Prince, D A Westerman, M M Wolf, D A Carney & J F Seymour

  2. Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

    K Yuen & J di Iulio

  3. School of Medicine, University of Melbourne, Melbourne, Australia

    H M Prince, M M Wolf & J F Seymour

Authors
  1. K E Herbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H M Prince
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D A Westerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M M Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D A Carney
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Yuen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J di Iulio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J F Seymour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J F Seymour.

Additional information

Research Institution: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herbert, K., Morgan, S., Prince, H. et al. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia 23, 305–312 (2009). https://doi.org/10.1038/leu.2008.302

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.302

Keywords

This article is cited by

Search

Advanced search

Quick links